US 12,459,895 B2
MEK inhibitors and uses thereof
Alfredo C. Castro, Somerville, MA (US); Michael J. Burke, Melrose, MA (US); Thomas A. Wynn, Lexington, MA (US); Sabine K. Ruppel, Cambridge, MA (US); Sergio L. Santillana Soto, Lexington, MA (US); Eric Haines, Andover, MA (US); Lan Xu, Wellesley, MA (US); and Oksana Zavidij, Westminster, MA (US)
Assigned to Ikena Oncology, Inc., Boston, MA (US)
Filed by Ikena Oncology, Inc., Boston, MA (US)
Filed on Nov. 13, 2023, as Appl. No. 18/507,616.
Application 18/507,616 is a division of application No. 18/323,700, filed on May 25, 2023, granted, now 11,878,958.
Claims priority of provisional application 63/488,807, filed on Mar. 7, 2023.
Claims priority of provisional application 63/479,131, filed on Jan. 9, 2023.
Claims priority of provisional application 63/375,875, filed on Sep. 16, 2022.
Claims priority of provisional application 63/345,698, filed on May 25, 2022.
Prior Publication US 2024/0190822 A1, Jun. 13, 2024
Int. Cl. C07D 213/64 (2006.01); A61P 35/00 (2006.01)
CPC C07D 213/64 (2013.01) [A61P 35/00 (2018.01)] 20 Claims
 
1. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound selected from:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.